Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3486649 | 0.75 | FFAR3 (0.35) | CA12CA1CA9KMT2ATSHR | |
| SCHEMBL5408573 | 0.75 | CA12 (0.33) | CA12CA1CA9KDM4E | |
| SCHEMBL8768383 | 0.73 | CA12 (0.32) | CA12CA1CA9KDM4E | |
| SCHEMBL8736481 | 0.73 | ALDH1A1 (0.38) | POLB | |
| Hydrochloric Acid SCHEMBL9812399 | 0.72 | OPRM1 (0.31) | KMT2ATDP1 | |
| SCHEMBL1769618 | 0.69 | HTT (0.37) | MEN1KMT2ASMN1; SMN2KDM4EPOLB | |
| SCHEMBL5469683 | 0.69 | — | — | |
| SCHEMBL18271092 | 0.69 | HTT (0.36) | CA12CA1CA9MEN1KMT2A | |
| Ethylenediamine SCHEMBL7125278 | 0.67 | KDM4E (0.31) | KDM4E | |
| SCHEMBL11711601 | 0.66 | NPSR1 (0.39) | CA12CA1CA9KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | 7 HILLS PHARMA INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12479820-B2 | Pyridin-3-yl derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-25 | — | — | US | disclosed |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | CHONGQING PHARMACEUTICAL RES INSTITUTE CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-12419874-B2 | GLP-1R agonist compound and use thereof | CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20250195481-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| EP-4033223-B1 | METHODS FOR THE RAPID PREPARATION OF LABELED GLYCOSYLAMINES AND FOR THE ANALYSIS OF GLYCOSYLATED BIOMOLECULES PRODUCING THE SAME | WATERS TECHNOLOGIES CORP (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025097835-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | 重庆医药工业研究院有限责任公司 | 2025-05-15 | — | — | WO | disclosed |
| WO-2025068371-A1 | INHIBITORS OF THE PROPROTEIN CONVERTASE FURIN, METHODS OF PRODUCTION THEREOF AND USE | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2025-04-03 | — | — | WO | disclosed |
| EP-4518842-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-113271939-B | Imidazole tetrazine compounds | 伊利诺伊大学董事会 | 2025-03-07 | — | — | CN | disclosed |
| WO-2007096395-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007082907-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| EP-1781667-A1 | BENZOTHIENOPYRIDINES FOR USE AS INHIBITORS OF EG5 KINESIN | Altana Pharma AG (DE) | 2007-05-09 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006083454-A1 | MULTICYCLIC BIS-AMIDE MMP INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | ALANTOS PHARMACEUTICALS, INC., | 2006-08-03 | — | — | US | disclosed |
| WO-2006018435-A1 | BENZOTHIENOPYRIDINES FOR USE AS INHIBITORS OF EG5 KINESIN | ALTANA PHARMA AG (DE) | 2006-02-23 | — | — | WO | disclosed |
| US-4003912-A | PREEMERGENCE HERBICIDES | MONSANTO COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195481-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | CA12 4487/4885CA1 4339/4885CA9 3647/4885 |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, MMP10 | CA12 281/4885CA1 316/4885CA9 219/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | CA12 3131/4885CA1 3183/4885CA9 484/4885 |
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | MMP13, MMP3, MMP11 | CA12 707/4885CA1 884/4885CA9 258/4885 |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | CD4, VCAM1, ITGA1 | CA12 925/4885CA1 813/4885CA9 1508/4885 |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | CA12 4487/4885CA1 4339/4885CA9 3647/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CA12 376/4885CA1 350/4885CA9 226/4885 |
| US-12419874-B2 | GLP-1R agonist compound and use thereof | GLP1R, GIPR, GPR119 | CA12 4487/4885CA1 4339/4885CA9 3647/4885 |
| US-12479820-B2 | Pyridin-3-yl derivatives | LPAR1, LPAR3, LPAR2 | CA12 4883/4885CA1 4871/4885CA9 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.